Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Goodwill & Intangibles (2023 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Goodwill & Intangibles for 3 consecutive years, with $48.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Goodwill & Intangibles fell 75.77% to $48.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $48.2 million, a 75.77% decrease, with the full-year FY2025 number at $48.2 million, down 75.77% from a year prior.
  • Goodwill & Intangibles was $48.2 million for Q4 2025 at Cartesian Therapeutics, down from $198.8 million in the prior quarter.
  • In the past five years, Goodwill & Intangibles ranged from a high of $198.8 million in Q4 2023 to a low of $48.2 million in Q1 2025.
  • A 3-year average of $149.1 million and a median of $174.7 million in 2023 define the central range for Goodwill & Intangibles.
  • Biggest YoY gain for Goodwill & Intangibles was 31.98% in 2025; the steepest drop was 75.77% in 2025.
  • Cartesian Therapeutics' Goodwill & Intangibles stood at $198.8 million in 2023, then changed by 0.0% to $198.8 million in 2024, then crashed by 75.77% to $48.2 million in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Goodwill & Intangibles are $48.2 million (Q4 2025), $198.8 million (Q3 2025), and $48.2 million (Q1 2025).